ONCOZ logo

OncoZenge AB (publ) Stock Price

OM:ONCOZ Community·SEK 64.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 2 Fair Values set on narratives written by author

ONCOZ Share Price Performance

SEK 5.12
-0.48 (-8.57%)
SEK 5.12
-0.48 (-8.57%)
Price SEK 5.12

ONCOZ Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Medium-low risk with adequate balance sheet.

6 Risks
2 Rewards

OncoZenge AB (publ) Key Details

SEK 2.8m

Revenue

SEK 0

Cost of Revenue

SEK 2.8m

Gross Profit

SEK 11.3m

Other Expenses

-SEK 8.6m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Feb 18, 2026
-0.68
100.00%
-307.40%
80.6%
View Full Analysis

About ONCOZ

Founded
2020
Employees
1
CEO
Stian Kildal
WebsiteView website
oncozenge.com

OncoZenge AB (publ), a pharmaceutical company, engages in the development of treatment for pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer in Sweden. It offers BupiZenge, which is in Phase 3 clinical trials for the treatment of pain in the oral cavity. The company was incorporated in 2020 and is headquartered in Bromma, Sweden.

Recent ONCOZ News & Updates

Recent updates

No updates